[go: up one dir, main page]

GB201603571D0 - Markers for skeletal disorders - Google Patents

Markers for skeletal disorders

Info

Publication number
GB201603571D0
GB201603571D0 GBGB1603571.9A GB201603571A GB201603571D0 GB 201603571 D0 GB201603571 D0 GB 201603571D0 GB 201603571 A GB201603571 A GB 201603571A GB 201603571 D0 GB201603571 D0 GB 201603571D0
Authority
GB
United Kingdom
Prior art keywords
markers
skeletal disorders
skeletal
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1603571.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Warwick
Original Assignee
University of Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Warwick filed Critical University of Warwick
Priority to GBGB1603571.9A priority Critical patent/GB201603571D0/en
Publication of GB201603571D0 publication Critical patent/GB201603571D0/en
Priority to PCT/GB2017/050546 priority patent/WO2017149300A1/en
Ceased legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/101Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/105Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/108Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
GBGB1603571.9A 2016-03-01 2016-03-01 Markers for skeletal disorders Ceased GB201603571D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1603571.9A GB201603571D0 (en) 2016-03-01 2016-03-01 Markers for skeletal disorders
PCT/GB2017/050546 WO2017149300A1 (en) 2016-03-01 2017-03-01 Markers for skeletal disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1603571.9A GB201603571D0 (en) 2016-03-01 2016-03-01 Markers for skeletal disorders

Publications (1)

Publication Number Publication Date
GB201603571D0 true GB201603571D0 (en) 2016-04-13

Family

ID=55807143

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1603571.9A Ceased GB201603571D0 (en) 2016-03-01 2016-03-01 Markers for skeletal disorders

Country Status (2)

Country Link
GB (1) GB201603571D0 (en)
WO (1) WO2017149300A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240019862A (en) 2017-09-01 2024-02-14 벤 바이오사이언시스 코포레이션 Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
PH12021552952A1 (en) 2019-07-12 2022-07-25 Alzchem Trostberg Gmbh Metastable crystal modification and method for the production thereof (i)
CN112782292B (en) * 2020-12-21 2023-04-07 浙江大学医学院附属邵逸夫医院 Application of metabolite ADMA in preparation of early osteoarthritis diagnosis kit
EP4565143A2 (en) * 2022-08-05 2025-06-11 Ochalski, Pawel G. Leaky joint syndrome diagnostics and treatments

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124071A1 (en) * 2003-09-30 2005-06-09 Kraus Virginia B. Methods and compositions for diagnosing musculoskeletal, arthritic and joint disorders by biomarker dating
US20070148704A1 (en) * 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
JP2010506147A (en) * 2006-09-29 2010-02-25 エフ.ホフマン−ラ ロシュ アーゲー Risk assessment of disease progression for patients with rheumatoid arthritis
CA2777800C (en) * 2009-10-15 2019-11-12 Crescendo Bioscience Biomarkers and methods for measuring and monitoring inflammatory disease activity
US10018591B2 (en) * 2012-06-11 2018-07-10 Preventage Healthcare, Llc Methods for improving diabetes management

Also Published As

Publication number Publication date
WO2017149300A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
DK3478217T3 (en) Historisk scanningsreference for intraorale scanninger
GB201602934D0 (en) Compounds
GB201620119D0 (en) Compounds
GB201619694D0 (en) Compounds
GB201604027D0 (en) Compounds
GB201604020D0 (en) Compounds
GB201610854D0 (en) Compounds
IL263228A (en) Benzoxaborole compounds
GB201608777D0 (en) Compounds
GB201613946D0 (en) Compounds
GB201604022D0 (en) Compounds
GB201604030D0 (en) Compounds
GB201603571D0 (en) Markers for skeletal disorders
GB201713217D0 (en) Compounds
GB201701455D0 (en) Neurodegenerative disorders
GB201621520D0 (en) Compounds
GB201622362D0 (en) Compounds
GB201604029D0 (en) Compounds
PL3601700T3 (en) Dividing member for boiserie
GB201622365D0 (en) Compounds
GB201407132D0 (en) Marker for neurodegenerative disorders
GB201604031D0 (en) Compounds
GB201712443D0 (en) Markers
GB201713179D0 (en) Fixing Marker
GB201720511D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)